Drug Profile
AHC 52
Latest Information Update: 14 Nov 2006
Price :
$50
*
At a glance
- Originator Kyorin Pharmaceutical
- Class Anti-ischaemics; Cardiotonics
- Mechanism of Action Glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Reperfusion injury
Most Recent Events
- 15 Jan 1998 New profile
- 15 Jan 1998 Preclinical development for Reperfusion injury in Japan (Unknown route)